{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:56:27Z","timestamp":1787756187500,"version":"build-2784847793"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,3]]},"abstract":"<jats:p>\n                    The appropriate treatment of osteoporosis and hypercalcemia using medications is important in patients with primary hyperparathyroidism (PHPT) who do not undergo parathyroidectomy. Denosumab effectively treats osteoporosis in patients with PHPT and improves hypercalcemia in the short term after administration. However, the medium-term effects of denosumab monotherapy on serum calcium levels and its safety in patients with PHPT remain unclear. In this study, we aimed to determine the medium-term effect of denosumab on serum calcium levels and bone mineral density (BMD) in patients. In this retrospective study, we compared serum calcium levels in patients with PHPT who did not undergo parathyroidectomy before denosumab monotherapy, 3 and 6 months after administration, respectively. Furthermore, we analyzed whether BMD increased 1 year after administration. Serum calcium levels in 15 patients with PHPT did not significantly change before (median serum calcium level, 10.8\u2005mg\/dL) or 6 months after denosumab administration (10.8\u2005mg\/dL). However, among 5 patients who visited the hospital for treatment of different diseases and whose serum calcium levels were measured 3 months after administration, their serum calcium levels significantly decreased after 3 months (from 10.6 to 9.8\u2005mg\/dL). No patient developed hypocalcemia. The BMD in the lumbar spine increased 12 months after denosumab administration (from 0.707 to 0.784\u2005g\/cm\n                    <jats:sup>2<\/jats:sup>\n                    ). These results suggest that denosumab administration alone is safe for hypocalcemia and effective for treating osteoporosis in patients with PHPT. In addition, it can be a good treatment option for patients who do not undergo parathyroidectomy.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000044882","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T20:08:06Z","timestamp":1759781286000},"page":"e44882","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness and safety of denosumab monotherapy in patients with primary hyperparathyroidism: A retrospective study"],"prefix":"10.1097","volume":"104","author":[{"given":"Akira","family":"Okada","sequence":"first","affiliation":[{"name":"Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7596-4715","authenticated-orcid":false,"given":"Ryuta","family":"Baba","sequence":"additional","affiliation":[{"name":"Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuria","family":"Ishibashi","sequence":"additional","affiliation":[{"name":"Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Otagaki","sequence":"additional","affiliation":[{"name":"Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaya","family":"Kodama","sequence":"additional","affiliation":[{"name":"Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gentaro","family":"Egusa","sequence":"additional","affiliation":[{"name":"Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaku","family":"Nagano","sequence":"additional","affiliation":[{"name":"Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuguka","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Hattori","sequence":"additional","affiliation":[{"name":"Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruya","family":"Ohno","sequence":"additional","affiliation":[{"name":"Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260526","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.path.2019.08.006","article-title":"Parathyroid pathology.","volume":"12","author":"Guilmette","year":"2019","journal-title":"Surg Pathol Clin"},{"key":"R2-20260526","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1210\/jc.2018-01225","article-title":"Primary hyperparathyroidism.","volume":"103","author":"Bilezikian","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"R3-20260526","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1210\/jc.2007-1215","article-title":"The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years.","volume":"93","author":"Rubin","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"R4-20260526","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis.","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"R5-20260526","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/jgs.15250","article-title":"Protective effect of denosumab on bone in older women with primary hyperparathyroidism.","volume":"66","author":"Eller-Vainicher","year":"2018","journal-title":"J Am Geriatr Soc"},{"key":"R6-20260526","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00198-019-05261-7","article-title":"Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?","volume":"31","author":"Tsvetov","year":"2020","journal-title":"Osteoporos Int"},{"key":"R7-20260526","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2014-1001","article-title":"Denosumab for treatment of hypercalcemia of malignancy.","volume":"99","author":"Hu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R8-20260526","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1530\/EC-20-0380","article-title":"Denosumab for management of severe hypercalcemia in primary hyperparathyroidism.","volume":"9","author":"Eremkina","year":"2020","journal-title":"Endocr Connect"},{"key":"R9-20260526","doi-asserted-by":"crossref","first-page":"8738959","DOI":"10.1155\/2016\/8738959","article-title":"Effect of denosumab on bone mineral density and markers of bone turnover among postmenopausal women with osteoporosis.","volume":"2016","author":"S\u00e1nchez","year":"2016","journal-title":"J Osteoporos"},{"key":"R10-20260526","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2169\/internalmedicine.56.7797","article-title":"Effects of denosumab on bone metabolic markers and bone mineral density in patients treated with glucocorticoids.","volume":"56","author":"Sawamura","year":"2017","journal-title":"Intern Med"},{"key":"R11-20260526","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00774-020-01153-7","article-title":"RANKL as a target for the treatment of osteoporosis.","volume":"39","author":"Matsumoto","year":"2021","journal-title":"J Bone Miner Metab"},{"key":"R12-20260526","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density.","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"key":"R13-20260526","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s12020-020-02401-6","article-title":"Effects of denosumab as compared with parathyroidectomy regarding calcium, renal, and bone involvement in osteoporotic patients with primary hyperparathyroidism.","volume":"69","author":"Miyaoka","year":"2020","journal-title":"Endocrine"},{"key":"R14-20260526","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S2213-8587(20)30063-2","article-title":"Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomized, double-blind, placebo-controlled, phase 3 trial.","volume":"8","author":"Leere","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R15-20260526","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1248\/bpb.b21-00653","article-title":"Risk analysis of denosumab-induced hypocalcemia in bone metastasis treatment: renal dysfunction is not a risk factor for its incidence in a strict denosumab administration management system with calcium\/vitamin D supplementation.","volume":"44","author":"Saito","year":"2021","journal-title":"Biol Pharm Bull"},{"key":"R16-20260526","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/ajco.12517","article-title":"Denosumab: prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures.","volume":"13","author":"Pittman","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"key":"R17-20260526","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1002\/jbmr.4679","article-title":"Classical and nonclassical manifestations of primary hyperparathyroidism.","volume":"37","author":"El-Haji Fuleihan","year":"2022","journal-title":"J Bone Miner Res"},{"key":"R18-20260526","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/0026-0495(86)90016-8","article-title":"Skeletal alkaline phosphatase activity as a bone formation index in vitro.","volume":"35","author":"Farley","year":"1986","journal-title":"Metabolism"},{"key":"R19-20260526","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0009-8981(83)90404-7","article-title":"Relationship of plasma tartrate resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism.","volume":"133","author":"Stepan","year":"1983","journal-title":"Clin Chim Acta"},{"key":"R20-20260526","doi-asserted-by":"crossref","first-page":"689","DOI":"10.20945\/2359-3997000000558","article-title":"Medical management of primary hyperparathyroidism.","volume":"66","author":"Bandeira","year":"2022","journal-title":"Arch Endocrinol Metab"},{"key":"R21-20260526","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment.","volume":"27","author":"Block","year":"2012","journal-title":"J Bone Miner Res"},{"key":"R22-20260526","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/jbmr.4804","article-title":"Hypocalcemia risk of denosumab across the spectrum of kidney disease: a population-based cohort study.","volume":"38","author":"Cowan","year":"2023","journal-title":"J Bone Miner Res"},{"key":"R23-20260526","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11657-021-00971-0","article-title":"Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety.","volume":"16","author":"Gopaul","year":"2021","journal-title":"Arch Osteoporos"},{"key":"R24-20260526","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2215\/CJN.0000000000000213","article-title":"Long-term effect of denosumab on bone disease in patients with CKD.","volume":"18","author":"Iseri","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"R25-20260526","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s12020-023-03381-z","article-title":"Denosumab for osteoporosis in patients with primary hyperparathyroidism and mild-to-moderate renal insufficiency.","volume":"81","author":"Gronskaya","year":"2023","journal-title":"Endocrine"},{"key":"R26-20260526","first-page":"143","article-title":"Bone type alkaline phosphatase as a bone formation marker: its role and advance in its measurement technologies [in Japanese].","volume":"58","author":"Ohta","year":"2012","journal-title":"Mod Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044882","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:26:19Z","timestamp":1779805579000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":26,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044882","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"2025-06-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}